Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients. 

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.